Suppr超能文献

应用于具有检测限的生物标志物的部分分类结果的治疗比较。

Treatment comparisons for a partially categorical outcome applied to a biomarker with assay limit.

作者信息

Chen Y H Joshua, Gould A Lawrence, Nessly Michael L

机构信息

Merck Research Laboratories, Blue Bell, PA 19422, USA.

出版信息

Stat Med. 2005 Jan 30;24(2):211-28. doi: 10.1002/sim.1833.

Abstract

The plasma level of HIV-RNA has been shown to be a strong prognostic biomarker for clinical progression and death in HIV infected patients and is widely used as the primary outcome in clinical trials to evaluate antiretroviral treatments. Currently approved assays to measure HIV-RNA levels have a lower limit of reliable quantification (LoQ). Current regulatory guidelines recommend using the proportion of patients achieving HIV-RNA levels below the assay limit at a certain time point (e.g. 24 or 48 weeks) as the primary endpoint for regulatory approval. However, a substantial decrease in HIV-RNA that does not go below the LoQ still is considered clinically beneficial for patients with advanced diseases who have failed many other therapies and are unlikely to maximally suppress the virus and achieve HIV-RNA levels below the LoQ. An experimental treatment may not be distinguishable from a control solely in terms of the proportions of patients whose HIV-RNA levels fall below the LoQ. The sensitivity of the comparison between the experimental treatment and the control could be increased by considering as well the difference between the treatments with respect to the HIV-RNA reductions of patients not achieving HIV-RNA levels below the LoQ. In this paper, we introduce a best-rank analysis which assigns the best rank to patients who achieve the HIV-RNA levels below the LoQ and applies the Mann-Whitney-Wilcoxon rank test to compare the two treatment groups. The Mann-Whitney-Wilcoxon statistic is shown to be a weighted sum of two statistics: one to compare the proportions of patients achieving the HIV-RNA levels below the LoQ and one to compare the viral reductions in patients with HIV-RNA levels above the LoQ. The corresponding statistical null and alternative hypotheses and the clinical interpretations of this best-rank test procedure are also discussed. An example is used to illustrate this approach and a simulation study is used to compare this approach with other methods.

摘要

HIV-RNA的血浆水平已被证明是HIV感染患者临床进展和死亡的强有力的预后生物标志物,并被广泛用作评估抗逆转录病毒治疗的临床试验的主要结局指标。目前批准的用于测量HIV-RNA水平的检测方法有一个可靠定量下限(LoQ)。当前的监管指南建议将在某个时间点(如24或48周)达到低于检测限的HIV-RNA水平的患者比例作为监管批准的主要终点。然而,对于那些已经失败了许多其他疗法且不太可能最大程度抑制病毒并使HIV-RNA水平低于LoQ的晚期疾病患者,HIV-RNA的大幅下降但未低于LoQ仍被认为具有临床益处。仅根据HIV-RNA水平低于LoQ的患者比例,一种实验性治疗可能无法与对照区分开来。通过考虑实验性治疗与对照在未达到低于LoQ的HIV-RNA水平的患者的HIV-RNA降低方面的差异,可提高两者比较的敏感性。在本文中,我们引入了一种最佳排名分析方法,该方法将最佳排名赋予达到低于LoQ的HIV-RNA水平的患者,并应用Mann-Whitney-Wilcoxon秩和检验来比较两个治疗组。结果表明,Mann-Whitney-Wilcoxon统计量是两个统计量的加权和:一个用于比较达到低于LoQ的HIV-RNA水平的患者比例,另一个用于比较HIV-RNA水平高于LoQ的患者的病毒载量降低情况。还讨论了相应的统计零假设和备择假设以及这种最佳排名检验程序的临床解释。通过一个例子来说明这种方法,并通过模拟研究将这种方法与其他方法进行比较。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验